{"id":"W2187343014","doi":"10.1016/s2352-3026(15)00197-0","title":"Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study","year":2015,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; Dalhousie University; Queen Elizabeth II Health Sciences Centre","funders":"AbbVie Biotherapeutics; National Cancer Institute; Celgene; Bristol-Myers Squibb","keywords":"Lenalidomide; Medicine; Multiple myeloma; Dexamethasone; Internal medicine; Clinical endpoint; Oncology; Phases of clinical research; Thalidomide; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001398663,0.0002463284,0.00100684,0.0001234848,0.0001220631,0.00005756608,0.0002927966,0.00008596364,0.000007756405],"category_scores_gemma":[0.001323127,0.0001207176,0.00001481857,0.0003845651,0.0002300865,0.0002068052,0.0001342563,0.000410643,0.00001124583],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001415292,"about_ca_system_score_gemma":0.000177293,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002210783,"about_ca_topic_score_gemma":0.004266961,"domain_scores_codex":[0.9971566,0.0009968039,0.0004975534,0.0004650798,0.0004538733,0.0004300999],"domain_scores_gemma":[0.997297,0.001532593,0.0002419887,0.0006145177,0.0001688382,0.0001451015],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4502256,0.01277315,0.5274171,0.0000163512,0.000185446,0.0005486017,0.002892396,0.00001349659,0.00003118163,0.00004375922,0.0002691816,0.005583659],"study_design_scores_gemma":[0.6717206,0.005093887,0.3198141,0.0001130982,0.00009527765,0.00004213724,0.0005661527,0.002184971,0.00008504267,0.0001303463,0.00004367383,0.0001107193],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9914812,0.0001313736,0.00006730235,0.002634523,0.0000348433,0.005340327,0.00007841082,0.00002730524,0.0002046715],"genre_scores_gemma":[0.9981137,0.00001628532,0.0008148929,0.0001570709,0.00003150138,0.0003674133,0.0004343236,0.00002600426,0.00003881988],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.221495,"threshold_uncertainty_score":0.4922722,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1136967265332321,"score_gpt":0.3721539367962131,"score_spread":0.258457210262981,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}